Drug Trial Radar · NCT04428333
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
117
Actual
Start
Aug 12, 2020
Primary completion
Apr 27, 2021
Study completion Sep 19, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II/III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx or larynx.
Conditions
- Neoplasms, Head and Neck
Interventions
FeladilimabDrug
Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
PembrolizumabDrug
Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
PlaceboDrug
Sterile normal saline
Platinum based chemotherapyDrug
Cisplatin/carboplatin
Fluorouracil (5FU)Drug
5-fluorouracil
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in mITT PopulationTime frame: Up to approximately 7 months
- OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 PopulationTime frame: Up to approximately 7 months
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT PopulationTime frame: Up to approximately 7 months
Locations
71 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Oro Verde Entre RIos, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Blacktown, Australia
GSK Investigational Site
Heidelberg, Australia
GSK Investigational Site
Melbourne, Australia
GSK Investigational Site
Woolangabba, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vitória, Brazil
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Copenhagen, Denmark
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Poitiers, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Hanover, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Ulm, Germany
GSK Investigational Site
Dublin, Ireland
GSK Investigational Site
Brescia, Italy
GSK Investigational Site
Florence, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Naples, Italy
GSK Investigational Site
Roma, Italy
GSK Investigational Site
Savona, Italy
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.